The role of AMH in anovulation associated with PCOS: a hypothesis
|
|
- Jocelyn Hodge
- 6 years ago
- Views:
Transcription
1 Human Reproduction, Vol.29, No.6 pp , 2014 Advanced Access publication on April 25, 2014 doi: /humrep/deu076 OPINION The role of AMH in anovulation associated with PCOS: a hypothesis Roy Homburg and Giselle Crawford* Homerton Fertility Centre, Homerton University Hospital, London E96SR, UK *Correspondence address. giselle.crawford@homerton.nhs.uk Submitted on January 15, 2014; resubmitted on March 17, 2014; accepted on March 20, 2014 abstract: Polycystic ovary syndrome (PCOS) is the most common cause of infertility due to anovulation. Despite its prevalence, the precise cause of the anovulation is yet to be clearly defined. There is an increased number of pre-antral and antral follicles in the polycystic ovary, many of which individually produce increased amounts of anti-müllerian hormone (AMH) compared with those in the normal ovary. In this article, it is hypothesized that the high AMH concentrations present in women with PCOS play an integral role in causing anovulation due to its inhibitory influence on the actions of follicle-stimulating hormone, which normally promotes follicular development from the small antral to the ovulatory stage. Key words: polycystic ovarian syndrome / anovulation / anti-müllerian hormone / pathophysiology Introduction Polycystic ovary syndrome (PCOS) is the most common cause of infertility due to anovulation and it is often diagnosed for the first time in the fertility clinic. Women with anovulatory or oligo-ovulatory PCOS will frequently exhibit other traits of the syndrome including hyperandrogenism, whether clinical and/or biochemical, and ultrasonic polycystic ovaries (Adams et al., 1986). The large disease burden of PCOS, affecting up to 10% of the female population, has led to much research into its aetiology, pathophysiology and management. In the beginning Stein and Leventhal first described PCOS in 1935 from their observations in seven patients with enlarged ovaries, amenorrhoea, infertility and hirsutism. They incorrectly hypothesized that the sclerocystic thickened cortex of the ovary was the primary aetiology of the condition and this appeared to be supported by the fact that ovulation was restored with bilateral wedge resection (Stein and Leventhal, 1935). It is now widely agreed that the basic lesion of PCOS lies in the ovaries themselves and that the hyperproduction of androgens by the ovaries is the basal endocrinological disturbance. Associated extra-ovarian factors such as insulin resistance and the consequent hyperinsulinaemia and elevated concentrations of luteinizing hormone(lh) play a part in exacerbating the problems and are all intertwined into an androgen circle (Homburg, 2009). Although PCOS is clearly familial in a large majority of cases, many years of searching for the culprit polymorphisms or combination of causative genes have not produced cogent results. This has led to the developmental theory of PCOS, based on the Barker hypothesis (Barker, 1990), that the offending genes are programmed by hyper-exposure to androgens in utero (Abbott et al., 2002). When Abbott et al. (2002) injected pregnant rhesus monkeys with testosterone, shown to reach the fetus, in adolescence the female offspring had a polycystic morphology of the ovaries, high-lh concentrations, hyperinsulinaemia and oligomenorrhoea compared with controls. Should the developmental theory of PCOS be verified in humans, the question remains as to the source of the excess androgens: are they coming from the mother or from the fetus? Numerous theories for the aetiology of the associated anovulation have been described, including an excess of small antral follicles, hyperandrogenaemia, hyperinsulinaemia and dysfunctional feedback mechanisms. While the severity of hyperandrogenaemia seems to correlate well with the severity of the ovulatory disturbance, there is a paucity of evidence for a direct effect of androgens in the inhibition of ovulation. Hyperinsulinaemia increases androgen production but again evidence for a direct inhibitory effect of insulin on the ovulatory process has not being forthcoming. While dysfunctional feedback mechanisms obviously play a part in the occurrence of anovulation, the changes in the feedback mechanisms are widely thought to be secondary to the primary pathophysiological changes in the ovary itself (Franks et al.,2006). Here, we present a hypothesis based upon recent research and introducing into the puzzle some new concepts, which may help to coordinate past theories. Follicle numbers in PCOS The density of pre-antral and small antral follicles in the polycystic ovary is six times that of the normal ovary (Webber et al., 2003). There are two possible reasons for this which are probably working in combination. & The Author Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please journals.permissions@oup.com
2 1118 Homburg and Crawford First, in the normal ovary, there is a constant dynamic progression of development from primordial follicles to primary, secondary, pre-antral and small antral follicles (Webber et al., 2003). This process seems to be accelerated in the polycystic ovary. In vitro experiments suggest that this acceleration is due to androgens (Hillier and Tetsuka, 1997; Vendola et al., 1999). Secondly, the fact that these small follicles do not develop into ovulatory follicles and also have a reduced rate of apoptosis compared with those in a normal ovary (Beloosesky et al., 2004) gives rise to the typical morphology of a polycystic ovary, a so-called stockpiling effect. Anti-Müllerian hormone As the name suggests, anti-müllerian hormone (AMH) has an integral role in the intrauterine development and sex differentiation of the male fetus. It is secreted from the Sertoli cells of the developing testes inhibiting ipsilateral mullerian duct development and thereby allowing the Wolffian duct system to prevail (Behringer et al., 1994). However, the role of AMH across the female reproductive life-span has only more recently come to light. It is a member of the transforming growth factor-beta (TGF-beta) protein super family and is produced exclusively by the gonads (Pepinsky et al., 1988). Along with other members of the TGF-beta superfamily, AMH plays an important role in folliculogenesis. In females, AMH is secreted by the granulosa cells of the early primordial follicles, thereafter its secretion increases and reaches peak concentration in small antral follicles before its level subsides in the granulosa cells of pre-ovulatory follicles (Durlinger et al., 2002; Andersen and Byskov, 2006). Owing to its strong correlation with the number of antral follicles, the AMH serum level is now well utilized as a marker for ovarian reserve and also as a prognostic marker for fertility potential (Fanchin et al., 2003; Muttukrishna et al., 2005; van Rooij et al., 2005). As women with PCOS have an increased number of small follicles in the pre-antral and antral stage, it is also not surprising that their AMH serum concentrations are higher than in women with normal ovaries. Since, Fallat et al. first reported this in 1997, several clinical studies have confirmed that serum AMH levels are two to three times higher in PCOS compared with levels in women with normal ovaries (Cook et al., 2002; Laven et al., 2004; Pigny et al., 2006). Laven et al. (2004) showed significantly elevated AMH levels in WHO II patients (that is normogonadotrophic normoestrogenic anovulatory patients; Rowe et al., 2000) compared with controls. Further, AMH levels were found to positively correlate with individual features of PCOS, including LH concentrations, testosterone, mean ovarian volume and the number of ovarian follicles (Laven et al., 2004). The overexpression of AMH and its receptors in oligo/anovulatory PCOS women could be due to increased LH levels and/or inhibition of its repressive action. This dysregulation is observed in oligo/anovulatory, but not in normo-ovulatory, PCOS women and this implicates LH in the follicular arrest of PCOS (Pierre et al., 2013). However, the positive correlation of AMH with testosterone concentrations does not necessarily imply a causal relationship. In fact, after androgen suppression AMH concentration was shown to be unchanged (Carlsen et al., 2009). A recent study supports the finding that the level of AMH can help to delineate between women with PCOS compared with women with polycystic ovarian morphology alone compared with controls (Homburg et al., 2013). Thus, not only is AMH elevated in women with PCOS but it also correlates with the severity of PCOS. However, it is not just the mere increased numbers of these follicles that produce raised AMH levels, as individual follicles from a polycystic ovary produce more AMH than their size-matched counterparts from a normal ovary. The AMH production from the granulosa cells of a patient with ovulatory PCOS is three times higher compared with granulosa cells from normal ovaries while, incredibly, the AMH production from sized matched granulosa cells of a patient with anovulatory PCOS is up to 75 times higher (Pellatt et al., 2007). Very recently, we have confirmed clinically that the individual granulosa cell produces more AMH than its counterpart in the normal ovary by calculating the ratio of AMH to antral follicle count. Interestingly, this ratio for women with polycystic ovaries but who are ovulatory falls between that of women who have normal ovaries and women with anovulatory PCOS (Bhide et al., submitted for publication). The role of AMH in the normal ovary While the exact function of AMH is yet to be completely clarified, there is evidence that it counteracts the actions of follicle-stimulating hormone (FSH) on aromatase activity and in the development of an ovulatory follicle (Pellatt et al., 2010, 2011). A number of animal and human studies collectively demonstrate an inhibitory role of AMH in follicular fluid. In murine granulosa cells, the FSH- and camp-stimulated aromatase activity was significantly reduced after treatment with AMH (Di Clemente et al., 1994). The same study revealed reduced mrna expression in campstimulated cells and decreased LH receptor numbers in porcine granulosa cells with AMH treatment (Di Clemente et al., 1994). Pellatt et al. (2011) revealed that AMH inhibits factors that promote follicle progression and growth in human granulosa cells. Grynberg et al. (2012) demonstrated in humans that AMH expression can be differentially regulated by estradiol depending on the estradiol receptors suggesting that its decrease in the granulosa cells of growing follicles, which mainly express estradiol receptor beta (ERb), is due to the effect of estradiol. Collectively, these effects of AMH would be expected to inhibit folliculogenesis or premature maturation in the normal ovary when the follicles remain at the small antral or antral stage. AMH production becomes almost undetectable once follicles reach.10 mm in size (Pellatt et al., 2007), allowing these follicles to become responsive to FSH and thereby allowing follicle selection to occur. Anovulation in PCOS It was first suggested by Dewailly et al. (2007) that the size of the 2 5 mm follicle pool is an independent and important contributor to the follicular arrest in PCOS. They had previously demonstrated that AMH serum concentrations were significantly higher in PCOS women who had amenorrhoea compared with those with oligomenorrhoea who, in turn, had higher levels than those who had normal cycles (Pigny et al., 2003). We have also demonstrated that oligo/anovulatory women with PCOS have significantly higher serum concentrations of AMH compared with women who have the typical morphology of a polycystic ovary but who are ovulatory (Homburg et al., 2013). Serum concentrations of FSH, although within normal limits, are generally lower in women with PCOS compared with women who have normal ovaries (Laven et al., 2004). This is not, however, enough to explain the cause of anovulation. Rather, there is an endogenous
3 Anovulation in PCOS 1119 inhibition of the action of FSH in promoting follicular development in women with PCOS. This endogenous inhibition may be overcome by administering exogenous FSH or, indeed, by promoting an FSH surge with clomiphene citrate. As AMH has been demonstrated to counteract the actions of FSH (Pellatt et al., 2010, 2011), it is suggested to be implicated in the cause of the anovulation in these women. This suggestion is reinforced by the fact that the higher the concentrations of AMH, the greater the severity of the ovulatory disturbance (Pigny et al., 2003; Laven et al., 2004). A further contribution of AMH to the mechanism of anovulation may be its positive correlation with LH concentrations (Laven et al., 2004; Piouka et al., 2009). LH is the principal promoter of androgen production by the ovary and more androgens are thought to encourage an acceleration of the progress of primordial to pre-antral and small antral follicles. These, in turn, produce AMH, thus creating a kind of vicious circle. The hypothesis of a positive feedback on the pituitary/hypothalamus is still poorly documented and we have cast further doubt on this with our finding of normal AMH values in 7 of 14 women with hypogonadotrophic hypogonadism (presently unpublished data). However, an additional factor could be that the lack of circulating progesterone in anovulatory women promotes the release of LH. This hypothesis for the aetiology of the anovulation associated with PCOS is summarized in Fig. 1. Indirect evidence to strengthen this hypothesis is provided by the fact that a reduction in the number of follicles is capable of restoring regular ovulation in oligo/anovulatory women with PCOS. When ovarian tissue is removed or destroyed, as in wedge resection of the ovaries or laparoscopic ovarian drilling, ovulation is frequently reinstated. Further, women with PCOS, over the age of 40, not infrequently resume normal regular cycles (Elting et al., 2003). These women, as is the case in normal women, have an accelerated loss of follicles at this age (and a decrease in AMH concentrations) and this, it is assumed, is the reason for the regulation of the cycle. Further indirect evidence to strengthen this hypothesis can be gathered from the practice of ovulation induction. Those with very high concentrations of circulating AMH are less likely to respond with ovulation to treatment with weight loss (Moran et al., 2007), clomiphene citrate or laparoscopic ovarian drilling (Amer et al., 2009). A possible reason that the metformin is less effective and certainly slower than clomiphene in inducing ovulation is the fact that AMH levels only decrease very slowly during this treatment (Fleming et al., 2005; Fabreques et al., 2011). Finally, AMH concentrations decrease during successful low-dose FSH therapy (Catteau-Jonard et al., 2007). Together, this clinical evidence accentuates the fact that the greater the number of follicles, the higher the AMH concentrations, the more severe the symptoms of PCOS. Other factors may influence AMH action. Activin may counter AMH action by inhibiting thecal androgen production, and follistatin, an activinbinding protein, neutralizes activin bioactivity (Duleba et al., 2001). Notably, in PCOS activin-a concentrations are decreased and follistatin concentrations are increased (Eldar-Geva et al., 2001; Norman et al., 2001). A decrease in concentration or functional activity of activin, as well as an increase in follistatin, might therefore also contribute to the pathophysiology of PCOS. Conclusions The greater the number of pre-antral and small antral follicles in the polycystic ovary, the greater the ovulatory disturbance. The number of these follicles is reflected by AMH concentrations in the serum. Both in vitro and clinical evidence has been presented here to support the hypothesis that the high-amh concentrations present in women with PCOS play an integral role in causing anovulation due to its inhibitory influence on the actions of FSH that normally promotes follicular development from the small antral stage to ovulation. Authors roles R.H. was responsible for the conception of the article. G.C. constructed the format of the manuscript and both authors were responsible for the writing and approval of the final version. Funding No funding was used and neither author had any conflict of interest. Conflict of interest None declared. Figure 1 A schematic representation of the proposed mechanism of anovulation in women with PCOS. AMH, anti-mullerian hormone; FSH, follicle stimulating hormone; LH, lutenizing hormone. References Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome a hypothesis. J Endocrinol 2002;174:1 5. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986; 293:
4 1120 Homburg and Crawford Amer SA, Li TC, Ledger WL. The value of measuring anti-müllerian hormone in women with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy. Hum Reprod 2009;24: Andersen CY, Byskov AG. Estradiol and regulation of anti-mullerian hormone, inhibin-a, and inhibin-b secretion: analysis of small antral and preovulatory human follicles fluid. J Clin Endocrinol Metab 2006;91:4064. Barker DJ. The fetal and infant origins of adult disease. Br Med J 1990; 301:1111. Behringer RR, Finegold MJ, Cate RL. Mullerian inhibiting substance function during mammalian sexual development. Cell 1994;79: Beloosesky R, Gold R, Almog B, Sasson R, Dantes A, Land-Bracha A, Hirsh L, Itskovitz-Eldor J, Lessing JB, Homburg R et al. Induction of polycystic ovary by testosterone in immature female rats: modulation of apoptosis and attenuation of glucose/insulin ratio. Int J Mol Med 2004;14: Carlsen S, Vanky E, Fleming R. Anti-Mullerian hormone concentrations in androgen-supressed women with polycystic ovary syndrome. Hum Reprod 2009;24: Catteau-Jonard S, Pigny P, Reyss AC, Decanter C, Poncelet E, Dewailly D. Changes in anti-müllerian hormone during low-dose FSH therapy for anovulation in PCOS. J Clin Endocrinol Metab 2007;92: Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum Mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovarian syndrome and normal women. Fertil Steril 2002;77: Dewailly D, Catteau-Jonard S, Reyss AC, Maunoury-Lefebvre C, Poncelet E, Pigny P. The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome. Hum Reprod 2007;22: Di Clemente N, Goxe B, Remmy J, Cate R, Josso N, Vigier B, Salesse R. Inhibitory effect of MAH upon the expression of aromatase and LH receptors by cultured granulose cells of rat and porcine immature ovaries. Endocrine 1994;2: Duleba A, Pehlivan T, Carbone R, Spaczynski R. Activin stimulates proliferation of rat ovarian thecal interstitial cells. Biol Reprod 2001; 65: Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, Uilenbroek JT, Grootegoed JA, Themmen AP. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002;143:1076. Eldar-Geva T, Spitz I, Groome N, Margoalioth E, Homburg R. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic-ovarian syndrome. Hum Reprod 2001;16: Elting MW, Kwee J, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril 2003;79: Fabreques F, Castelo-Branco C, Carmona F, Guimerá M, Casamitjana R, Balasch J. The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive age. Gynecol Endocrinol 2011;27: Fallat ME, Cook C, Siow Y, Carrilo A, Marra M. Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovarian syndrome, and endometriosis. Fertil Steril 1997;67: Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18: Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB. Metformin reduces serum Müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 2005;83: Franks S, McCarthy MI, Hardy K. Development of polycystic ovarysyndrome: involvement of genetic and environmental factors. Int J Androl. 2006; 29: Grynberg M, Pierr A, Rey R, Leclerc A, Arouche N, Hesters L, Catteau-Jonard S, Frydman R, Picard JY, Fanchin R et al. Differential regulation of ovarian anti-mullerian hormone (AMH) by estradiol through a- and b-estrogen receptors. J Clin Endocrinol Metab 2012; 97: Hillier SG, Tetsuka M. Role of androgens in follicle maturation and atresia. Ballière s Clin Obstet Gynaecol 1997;11: Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod 2009;24: Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, Grayson K. The relationship of serum anti-müllerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod 2013;28: Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Müllerian hormone serum concentrations in normo-ovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89: Moran LJ, Noakes M, Clifton PM, Norman RJ. The use of anti-müllerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92: Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? Br J Obstet Gynaecol 2005;112: Norman R, Milner C, Groome N, Robertson D. Circulating follistatin concentrations are higher and activin concentrations are lower in polycystic ovarian syndrome. Hum Reprod 2001;16: Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, Mason H. Granulosa cell production of anti-müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007;92: Pellatt L, Rice S, Mason HD. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 2010;139: Pellatt L, Rice S, Dilaver N, Heshri A, Galea R, Brincat M, Brown K, Simpson ER, Mason HD. Anti-Müllerian hormone reduces follicle sensitivity to follicle-stimulating hormone human granulosa cells. Fertil Steril 2011;96: Pepinsky RB, Sincalir LK, Chow EP, Mattaliano RJ, Manganaro TF, Donahoe PK, Cate RL. Proteolytic processing of Mullerian inhibiting substance produces a transforming growth factor beta like fragment. J Biol Chem 1988;263: Pierre A, Peigne M, Gynberg M, Arouche N, Taieb J, Hesters L, Gonzalès J, Picard JY, Dewailly D. Fanchin loss of LH-induced down-regulation of anti-mullerian hormone receptor expression may contribute to anovulation in women with polycystic ovarian syndrome. Hum Reprod 2013;28: Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-mullerian hormone as a surrogate marker for antral follicle count for definition of the polycystic ovarian syndrome. J Clin Endocrinol Metab 2006;91: Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D. Elevated serum level of anti-müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003; 88: Piouka A, Famakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009;296: E238 E243.
5 Anovulation in PCOS 1121 Rowe PJ, Comhaire FH, Hargreave TB, Mellows H. Female partner. In: Rowe PJ, Comhaire FH, Hargreave TB, Mellows H (eds). WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple. Cambridge, UK: Press Syndicate of the University of Cambridge 2000; Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29: Van Rooij IA, Baroekmans FJ, Scheffer GJ, Looman CW, Habbema JD, De Jong FH, Fauser BJ, Themmen AR, te Velde ER. Serum anti-mullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005;83:979. Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M, Bondy CA. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod 1999;61: Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, Franks S. Formation and early development of follicles in the polycystic ovary. Lancet 2003;362:
The relationship of serum anti- Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study
Human Reproduction, Vol.0, No.0 pp. 1 7, 2013 doi:10.1093/humrep/det015 Hum. Reprod. Advance Access published February 1, 2013 ORIGINAL ARTICLE Reproductive endocrinology The relationship of serum anti-
More informationInternational Journal of Pharma and Bio Sciences ENDOCRINE MARKERS AND DECLINE IN REPRODUCTIVE POTENTIAL OF WOMEN ABSTRACT
Research Article Biochemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 ENDOCRINE MARKERS AND DECLINE IN REPRODUCTIVE POTENTIAL OF WOMEN BUSHRA FIZA *, 1, 2, RATI MATHUR 2, MAHEEP
More informationANTI-MÜLLERIAN HORMONE (AMH) AS A USEFUL MARKER IN DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME
General Endocrinology ANTI-MÜLLERIAN HORMONE (AMH) AS A USEFUL MARKER IN DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME Laura Leonte 1,2, M. Coculescu 3, S. Radian 3, Simona Fica 4, Andra Caragheorgheopol 3, B.
More informationReproduction. AMH Anti-Müllerian Hormone. Analyte Information
Reproduction AMH Anti-Müllerian Hormone Analyte Information - 1-2011-01-11 AMH Anti-Müllerian Hormone Introduction Anti-Müllerian Hormone (AMH) is a glycoprotein dimer composed of two 72 kda monomers 1.
More informationLille II; and b Laboratory of Endocrinology, C.H.R.U. and Universite de Lille II, Lille, France
Increased anti-m ullerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization Virginie Desforges-Bullet,
More informationThe excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome
Human Reproduction Vol.22, No.6 pp. 1562 1566, 2007 Advance Access publication on April 20, 2007 doi:10.1093/humrep/dem060 The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated
More informationAnti-Müllerian hormone: a new marker for ovarian function
REPRODUCTION REVIEW Anti-Müllerian hormone: a new marker for ovarian function Jenny A Visser, Frank H de Jong, Joop S E Laven 1 and Axel P N Themmen Department of Internal Medicine and 1 Division of Reproductive
More informationInterrelationships among reproductive hormones and antral follicle count in human menstrual
Page 1 of 29 Endocrine Connections Publish Ahead of Print, published on November 17, 216 as doi:1.153/ec-16-77 1 EC-16-3R1 Interrelationships among reproductive hormones and antral follicle count in human
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationMetformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D., a Lyndal Harborne, B.Med., a David T. MacLaughlin,
More informationSerum anti-mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism
Human Reproduction Page 1 of 6 Hum. Reprod. Advance Access published March 31, 2005 doi:10.1093/humrep/deh873 Serum anti-mullerian hormone levels during controlled ovarian hyperstimulation in women with
More informationS. AMH in PCOS Research Insights beyond a Diagnostic Marker
S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationIntroduction. Luciano G. Nardo 1,4, Allen P. Yates 2, Stephen A. Roberts 3, Phil Pemberton 2, and Ian Laing 2
Human Reproduction, Vol.24, No.11 pp. 2917 2923, 2009 Advanced Access publication on July 18, 2009 doi:10.1093/humrep/dep225 ORIGINAL ARTICLE Reproductive endocrinology The relationships between AMH, androgens,
More informationDepartment of Obstetrics and Gynecology, Benha Faculty of Medicine, Benha University, Egypt
Impact of laparoscopic ovarian drilling on anti-m ullerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women with anovulatory polycystic ovary syndrome Ashraf
More informationSerum anti-muè llerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3
Human Reproduction Vol.18, No.2 pp. 323±327, 2003 DOI: 10.1093/humrep/deg042 Serum anti-muè llerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and
More informationCORRELATIONS BETWEEN ANTI-MÜLLERIAN HORMONE, INHIBIN B, AND ACTIVIN A IN FOLLICULAR FLUID IN IVF/ICSI PATIENTS FOR ASSESSING
604 EU RO PE AN JOUR NAL OF MED I CAL RE SEARCH December 14, 2007 Eur J Med Res (2007) 12: 604-608 I. Holzapfel Publishers 2007 CORRELATIONS BETWEEN ANTI-MÜLLERIAN HORMONE, INHIBIN B, AND ACTIVIN A IN
More informationIN VITRO FERTILIZATION
FERTILITY AND STERILITY VOL. 82, NO. 5, NOVEMBER 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. IN VITRO FERTILIZATION Serum
More informationAnti-Müllerian hormone and polycystic ovary syndrome: a mountain too high?
REPRODUCTION REVIEW Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Laura Pellatt, Suman Rice and Helen D Mason Basic Medical Sciences, St George s, University of London, Cramner
More informationAge-Specific Serum Anti-Mullerian Hormone and Follicle Stimulating Hormone Concentrations in Infertile Iranian Women
Original Article Age-Specific Serum Anti-Mullerian Hormone and Follicle Stimulating Hormone Concentrations in Infertile Iranian Women Alireza Raeissi, M.Sc. 1, Alireza Torki, M.Sc. 1, Ali Moradi, Ph.D.
More informationOriginal Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al
Original Investigation Sensitivity and specificity of anti-mülerian hormone in the diagnosis of polycystic ovary syndrome in a macedonian population of women of reproductive age: a cross-sectional study
More informationOriginal Article. Razieh Dehghani-Firouzabadi MD *, Naeimeh Tayebi MD*, Maryam Asgharnia MD*
Arch Iranian Med 2008; 11 (4): 371 376 Original Article Serum Level of Anti-Mullerian Hormone in Early Follicular Phase as a Predictor of Ovarian Reserve and Pregnancy Outcome in Assisted Reproductive
More informationEXCEPTIONAL DIAGNOSTICS FOR REPRODUCTIVE DISEASE STATE MANAGEMENT. Anti-Müllerian Hormone (AMH)
EXCEPTIONAL DIAGNOSTICS FOR REPRODUCTIVE DISEASE STATE MANAGEMENT Anti-Müllerian Hormone (AMH) Table of Contents» Introduction... 3» Biosynthesis... 3» Physiological Function... 4 Fetal Stage... 4 Postnatal
More informationIs polycystic ovary syndrome an exception for reproductive aging?
Human Reproduction, Vol.25, No.7 pp. 1775 1781, 2010 Advanced Access publication on April 30, 2010 doi:10.1093/humrep/deq088 ORIGINAL ARTICLE Reproductive endocrinology Is polycystic ovary syndrome an
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationPredictive markers for the FSH sensitivity of women with polycystic ovarian syndrome
Human Reproduction, Vol.29, No.3 pp. 518 524, 2014 Advanced Access publication on January 12, 2014 doi:10.1093/humrep/det468 ORIGINAL ARTICLE Infertility Predictive markers for the FSH sensitivity of women
More informationThe Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page
The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page 1278-1288 Anti-Mullerian Hormone: An Indicator for the Severity of Polycystic Ovarian Syndrome Yehia Abd-Elsalam Wafa 1, Mohamed
More informationCan high serum anti-müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?
ORIGINAL ARTICLE http://dx.doi.org/1.5653/cerm.213.4.3.135 pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 213;4(3):135-14 Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationAnti Müllerian Hormone (AMH) level and expression in mural and cumulus cells in relation to age
Kedem et al. Journal of Ovarian Research 214, 7:113 RESEARCH Open Access Anti Müllerian Hormone (AMH) level and expression in mural and cumulus cells in relation to age Alon Kedem 1*, Yuval Yung 1, Gil
More informationArticle Anti-Müllerian hormone: clinical insights into a promising biomarker of ovarian follicular status
RBMOnline - Vol 12 No 6. 2006 695-703 Reproductive BioMedicine Online; www.rbmonline.com/article/2207 on web 3 April 2006 Article Anti-Müllerian hormone: clinical insights into a promising biomarker of
More informationSenior resident 5 lll rd year P.G. student
International Journal of scientific research and management (IJSRM) Volume 4 Issue 06 Pages 4253-4261 2016 Website: www.ijsrm.in ISSN (e): 2321-3418 An Observational Cross Sectional Study Of Serum Anti-Mullerian
More informationE. Arbo 1, D.V. Vetori, M.F. Jimenez, F.M. Freitas, N. Lemos and J.S. Cunha-Filho
Human Reproduction Vol.22, No.12 pp. 3192 3196, 2007 Advance Access publication on November 2, 2007 doi:10.1093/humrep/dem258 Serum anti-müllerian hormone levels and follicular cohort characteristics after
More informationSERUM ANTI- MULLERIAN HORMONE IS A BETTER PREDICTOR OF OVARIAN RESERVE AT THE EARLY FOLLICULAR PHASE.
SERUM ANTI- MULLERIAN HORMONE IS A BETTER PREDICTOR OF OVARIAN RESERVE AT THE EARLY FOLLICULAR PHASE. Ashraf Hany Abdel Rahman. MD. (1)&(3), Samir Mohamed Elsaid (I) and Hadeer Aly Abb assy. MD. (2) (l)
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationEarly follicular anti-mullerian hormone as a predictor of ovarian response during ICSI cycles
Middle East Fertility Society Journal (2010) 15, 281 287 Middle East Fertility Society Middle East Fertility Society Journal www.mefsjournal.com www.sciencedirect.com ORIGINAL ARTICLE Early follicular
More informationArticle Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?
RBMOnline - Vol 16. No 5. 2008 664-670 Reproductive BioMedicine Online; www.rbmonline.com/article/3179 on web 11 March 2007 Article Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality
More informationMETABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationMain outcome measures HIFU treatment did not affect the ovarian function.
DOI: 10.1111/1471-0528.14739 www.bjog.org Uterine Fibroids & Adenomyosis Changes in anti-m ullerian hormone levels as a biomarker for ovarian reserve after ultrasoundguided high-intensity focused ultrasound
More informationIncreased Anti-Müllerian Hormone Serum Concentrations in Prepubertal Daughters of Women with Polycystic Ovary Syndrome
Increased Anti-Müllerian Hormone Serum Concentrations in Prepubertal Daughters of Women with Polycystic Ovary Syndrome Teresa Sir-Petermann, Ethel Codner, Manuel Maliqueo, Bárbara Echiburú, Catalina Hitschfeld,
More informationEndocrine control of female reproductive function
Medicine School of Women s & Children s Health Discipline of Obstetrics & Gynaecology Endocrine control of female reproductive function Kirsty Walters, PhD Fertility Research Centre, School of Women s
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationBasal level of anti-müllerian hormone is associated with oocyte quality in stimulated cycles
Human Reproduction Vol.21, No.8 pp. 2022 2026, 2006 Advance Access publication May 5, 2006. doi:10.1093/humrep/del127 Basal level of anti-müllerian hormone is associated with oocyte quality in stimulated
More informationREVIEW. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. Majid Bani Mohammad 1, Abbas Majdi Seghinsara 2 * Abstract.
DOI:10.22034/APJCP.2017.18.1.17 REVIEW Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH Majid Bani Mohammad 1, Abbas Majdi Seghinsara 2 * Abstract The polycystic ovary syndrome (PCOS) is
More informationENDOCRINE CHARACTERISTICS OF ART CYCLES
ENDOCRINE CHARACTERISTICS OF ART CYCLES DOÇ. DR. SEBİHA ÖZDEMİR ÖZKAN KOCAELI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, IVF UNIT 30.04.2014, ANTALYA INTRODUCTION The endocrine
More information'The effect of weight loss on anti-müiierian hormone levels in overweight and obese women with
The effect of weight loss on anti-müiierian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment This is the author submitted original manuscript (pre-print)
More informationINTRODUCTION. Address for correspondence Seok Hyun Kim, M.D. J Korean Med Sci 2008; 23: ISSN DOI: /jkms
J Korean Med Sci 2008; 23: 657-61 ISSN 1011-8934 DOI: 10.3346/jkms.2008.23.4.657 Copyright The Korean Academy of Medical Sciences Serum Anti-Mullerian Hormone and Inhibin B Levels at Ovulation Triggering
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationBJMHR British Journal of Medical and Health Research Journal home page:
RESEARCH ARTICLE Br J Med Health Res. 2015; 2(11) ISSN: 2394-2967 BJMHR British Journal of Medical and Health Research Journal home page: www.bjmhr.com Comparision of Anti- Mullerian and Testosternoe Hormones
More informationNormal serum concentrations of anti-müllerian hormone in women with regular menstrual cycles
Reproductive BioMedicine Online (2010) 21, 463 469 www.sciencedirect.com www.rbmonline.com ARTICLE Normal serum concentrations of anti-müllerian hormone in women with regular menstrual cycles A La Marca
More informationAbstract. Introduction. RBMOnline - Vol 18. No Reproductive BioMedicine Online; on web 20 March 2009
RBMOnline - Vol 18. No 5. 2009 694-699 Reproductive BioMedicine Online; www.rbmonline.com/article/3738 on web 20 March 2009 Article Anti-Müllerian hormone in pregnant women in relation to other hormones,
More informationAnti-müllerian hormone is a glycoprotein known for
Is There a Place for AMH Testing in Canada? Jordan A. Green, BSc, 1 Gillian Graves, MD, FRCSC 2 1 Department of Medicine, Dalhousie University, Halifax NS 2 Department of Obstetrics and Gynaecology, IWK
More informationThe Relation of Serum Anti-Mullerian Hormone with Polycystic Ovary Syndrome: Correlation with Clinical and Hormonal Parameters
The Relation of Serum Anti-Mullerian Hormone with Polycystic Ovary Syndrome: Correlation with Clinical and Hormonal Parameters Alaa Mohammed Sadiq ( M.B.Ch.B, FICOG, DGO) obstetrics and gynecology, college
More informationFollicle dynamics and anovulation in polycystic ovary syndrome
Human Reproduction Update, Vol.14, No.4 pp. 367 378, 2008 Advance Access publication May 22, 2008 doi:10.1093/humupd/dmn015 Follicle dynamics and anovulation in polycystic ovary syndrome Stephen Franks
More informationPrognosticating ovarian reserve by the new ovarian response prediction index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Tak A et al. Int J Reprod Contracept Obstet Gynecol. 2018 Mar;7(3):1196-1200 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20180917
More informationThesis. Mahmoud Sedki Yassin (MsC) Cairo University. Under supervision of
Serum anti-mullerian hormone level and antral follicle count in patients with endometriomas pre and post endometriotic surgery for assessment of ovarian reserve Thesis Submitted for partial fulfillment
More informationREPRODUCTIVE ENDOCRINOLOGY
FERTILITY AND STERILITY VOL. 77, NO. 2, FEBRUARY 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. REPRODUCTIVE ENDOCRINOLOGY
More informationThe intra-follicular molecular biology mandating advancement of egg retrieval in some women
The intra-follicular molecular biology mandating advancement of egg retrieval in some women David H. Barad, USA Director of Assisted Reproductive Technology, The Center for Human Reproduction New York
More informationPattern of Serum Inhibin B Hormone Secretion in Polycystic Ovarian Disease
Med. J. Cairo Univ., Vol. 82, No. 2, September: 119-123, 2014 www.medicaljournalofcairouniversity.net Pattern of Serum Inhibin B Hormone Secretion in Polycystic Ovarian Disease AHMED M. AWADALLA, M.D.;
More informationSerum müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome
Serum müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome Yong Siow, Ph.D., a Sari Kives, M.D., c Paige Hertweck, M.D., b Sally Perlman,
More informationEffects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation
Human Reproduction pp. 1 6, 2007 Hum. Reprod. Advance Access published December 15, 2007 doi:10.1093/humrep/dem388 Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation
More informationAnti-Mullerian Hormone as a Predictive Factor in Assisted Reproductive Technique of Polycystic Ovary Syndrome Patients
ORIGINAL REPORT Anti-Mullerian Hormone as a Predictive Factor in Assisted Reproductive Technique of Polycystic Ovary Syndrome Patients Ashraf Aleyasin, Marzie Aghahoseini, Sara Mokhtar, and Parvin Fallahi
More informationAMH and PCOS phenotypes. Miro Šimun Alebić, Nataša Stojanović, Alain Duhamel, Dedier DewaIly
AMH and PCOS phenotypes Miro Šimun Alebić, Nataša Stojanović, Alain Duhamel, Dedier DewaIly and- Müllerian hormone (AMH) is produced by granulosa cells (GCs) of growing follicles Weenen et al., 2004; Jeppesen
More informationAlthough polycystic ovary syndrome
PART 4 OF A 4-PART E-SERIES Polycystic ovary syndrome: Cosmetic and dietary approaches What we know about treatment of hirsutism and acne, the effects of weight loss, and emerging diagnostic tests Steven
More informationThe association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age
Reproductive BioMedicine Online (2010) 21, 757 761 www.sciencedirect.com www.rbmonline.com ARTICLE The association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age Jeff G
More informationQuantitative analysis of antral follicle number and size: a comparison of two-dimensional and automated three-dimensional ultrasound techniques
Ultrasound Obstet Gynecol 2010; 35: 354 360 Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.7505 Quantitative analysis of antral follicle number and size: a comparison
More informationAntim ullerian hormone and polycystic ovary syndrome
Antim ullerian hormone and polycystic ovary syndrome Yi-Hui Lin, M.D., a Wan-Chun Chiu, Ph.D., c Chien-Hua Wu, Ph.D., b,e Chii-Ruey Tzeng, M.D., d Chun-Sen Hsu, M.D., a and Ming-I Hsu, M.D. a a Department
More informationAntral follicle count as a predictor of ovarian response
Original article Antral follicle count as a predictor of ovarian response N. Lonegro a, N. Napoli a,*, R. Pesce b and C. Chacón a a Imaging Department, Hospital Italiano de Buenos Aires, Ciudad Autónoma
More informationPolycystic Ovary Syndrome
What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular
More informationIs ovarian reserve diminished after laparoscopic ovarian drilling?
Gynecological Endocrinology, March2009;25(3):159 165 OVARY Is ovarian reserve diminished after laparoscopic ovarian drilling? MURAT API Haseki Education and Research Hospital, Istanbul, Turkey (Received
More informationClinical uses of anti-m ullerian hormone assays: pitfalls and promises
Clinical uses of anti-m ullerian hormone assays: pitfalls and promises Isabelle Streuli, M.D., a Timothee Fraisse, M.D., M.Sc., a Charles Chapron, M.D., b Gerard Bijaoui, M.D., b Paul Bischof, Ph.D., a
More informationInhibin B and anti-mullerian hormone: markers of ovarian response in IVF/ICSI patients?
BJOG: an International Journal of Obstetrics and Gynaecology November 2004, Vol. 111, pp. 1248 1253 DOI: 10.1111/j.1471-0528.2004.00452.x Inhibin B and anti-mullerian hormone: markers of ovarian response
More informationStudentoppgave. Veileder: Dr. med Jan Mellembakken, overlege Kvinneklinikken, Rikshospitalet. Profesjonsstudiet i Medisin
Studentoppgave Maintained number of oocytes with advanced age in PCOS women during IVF treatment compared to controls Mirjam Kilen Veileder: Dr. med Jan Mellembakken, overlege Kvinneklinikken, Rikshospitalet
More informationCASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?
CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,
More informationAnti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome
European Journal of Endocrinology (2009) 160 847 853 ISSN 0804-4643 CLINICAL STUDY Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationPolycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology
Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationCorrelation of Anti-Mullerian Hormone with clinical, hormonal and ultrasonographic parameters in PCOS and normo-ovulatory women
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 2 Ver. VIII (February. 2017), PP 51-56 www.iosrjournals.org Correlation of Anti-Mullerian Hormone
More informationInfertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery
Macut D, Pfeifer M, Yildiz BO, Diamanti-Kandarakis E (eds): Polycystic Ovary Syndrome. Novel Insights into Causes Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications
More informationRole of Anti-Müllerian Hormone in Gynecology: A Review of Literature
review article Role of Anti-Müllerian Hormone 10.5005/jp-journals-10016-1102 in Gynecology: A Review of Literature Role of Anti-Müllerian Hormone in Gynecology: A Review of Literature 1 Naina Kumar, 2
More informationAnti-Müllerian Hormone Levels in the Follicular Fluid of the Preovulatory Follicle: A Predictor for Oocyte Fertilization and Quality of Embryo
ORIGINAL ARTICLE Obstetrics & Gynecology http://dx.doi.org/1.3346/jkms.214.29.9.1266 J Korean Med Sci 214; 29: 1266-127 Anti-Müllerian Hormone Levels in the Follicular Fluid of the Preovulatory Follicle:
More informationLH activity administration during the
LH activity administration during the luteal-follicular transition Richard Fleming On behalf of the Luveris Pre-treatment group University of Glasgow Scotland Androgens have a Paracrine action in the Early
More informationReproductive outcome in women with body weight disturbances
Reproductive outcome in women with body weight disturbances Zeev Shoham M.D. Dep. Of OB/GYN Kaplan Hospital, Rehovot, Israel Weight Status BMI (kg/m 2 ) Underweight
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More informationAnti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool?
Clinical Endocrinology (2006) 64, 603 610 doi: 10.1111/j.1365-2265.2006.02533.x REVIEW ARTICLE Blackwell Publishing Ltd Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating
More informationIVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman
IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major
More informationOvarian Steroidogenic Abnormalities in the Polycystic Ovary Syndrome
Chapter 18 / Steroidogenesis in PCOS 203 18 Ovarian Steroidogenic Abnormalities in the Polycystic Ovary Syndrome Denis A. Magoffin SUMMARY Excess androgen biosynthesis is a diagnostic feature of polycystic
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationSerum Vascular Endothelial Growth Factor in Polycystic Ovary Syndrome and its Relation to Ovarian Drilling
Available online on www.ijtpr.com International Journal of Toxicological and Pharmacological Research 2014; 6(4): 123-127 Research Article ISSN: 0975-5160 Serum Vascular Endothelial Growth Factor in Polycystic
More informationREPRODUCTIVE CYCLE OF FEMALE MAMMAL
REPRODUCTIVE CYCLE OF FEMALE MAMMAL Fig. 8-12 Secondary follicles growing follicles increase in number of layers of granulosa cells Tertiary follicles maturing follicles antrum formation fluid filled space
More informationReproduction. Inhibin B. Analyte Information
Reproduction Inhibin B Analyte Information - 1-2011-01-11 Inhibin B Introduction Inhibins are polypeptides belonging to the transforming growth factor-β (TGF-β) superfamily which also includes TGF-β, activin
More informationJMSCR Vol 06 Issue 09 Page September 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i9.53 Role of Anti-Mullerian Hormone
More informationAge specific serum anti-müllerian hormone levels in 1,298 Korean women with regular menstruation
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2011;38(2):93-97 Age specific serum anti-müllerian hormone levels in 1,298 Korean women with regular menstruation Ji Hee Yoo, Hye Ok
More informationDifferentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-müllerian hormone cutoff value
ORIGINAL ARTICLE Korean J Intern Med 2017;32:690-698 Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-müllerian hormone cutoff value Do Kyeong Song,
More informationoriginal article INTRODUCTION Since the introduction of anti-müllerian hormone ABSTRACT
original article Age related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center Batool Hossein Rashidi
More informationAnti-Mullerian hormone (AMH) as predictor of ovarian reserve
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Shembekar CA et al. Int J Reprod Contracept Obstet Gynecol. 2017 Sep;6(9):4006-4010 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20174053
More informationAnti-Müllerian hormone as a predictor of pregnancy following IVF
Reproductive BioMedicine Online (2013) 26, 247 252 www.sciencedirect.com www.rbmonline.com ARTICLE Anti-Müllerian hormone as a predictor of pregnancy following IVF Priya Bhide a, *, Anil Gudi a, Amit Shah
More informationThe use of insulin sensitising agents in ovulation induction in women with Polycystic Ovary Syndrome
HORMONES 2006, 5(3):171-178 Review The use of insulin sensitising agents in ovulation induction in women with Polycystic Ovary Syndrome Richard Fleming University of Glasgow and Division of Developmental
More information